Sciclone Pharmaceuticals (SCLN) Inactive 10-Q2007 Q1 Quarterly report

Filed: 8 May 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Good

New words: accelerate, accuracy, adhere, aggregate, Alfred, Avantogen, began, brand, Canada, Canadian, carcinoma, component, conclusion, declared, detailed, deterring, downturn, economy, eliminated, entrance, examination, fastest, FIN, firm, Food, fourth, framework, front, GAAP, gemcitabine, Gmbh, guidance, HCC, headcount, hepatocellular, ineffective, intercompany, invoiced, likelihood, median, Mexican, mitigate, multiplied, Oncology, open, opportunity, original, pancreatic, par, paragraph, party, pilot, portion, proceed, reduction, RESprotect, reveal, risky, Rudolph, run, satisfactorily, Secretary, SFDA, shorter, slightly, subscription, suspended, terminated, thymalfasin, today, unforeseen, unrecognized, upfront, wholly, world

Removed: account, accrue, adjusted, agency, agreed, anniversary, annually, APB, appointment, approximate, assist, audit, automatically, bacterial, basic, building, carrying, CEO, classification, commenced, Committee, conform, consecutive, constant, consultant, correct, correctly, decreased, dedicated, determining, dispute, distinguishable, Dr, encounter, evidence, excluding, expensed, exposure, familiarity, field, forma, formed, free, generated, greater, hypothetical, impairment, implied, increasingly, Initial, intensive, internationally, issuable, Item, KK, leverage, maturity, maximizing, maximum, measurement, Meeting, member, metropolitan, minimal, minimize, monitoring, monthly, municipal, nonemployee, nonqualified, nonstatutory, notably, PCAOB, permitted, Plough, prescribing, president, pro, promising, promoting, provision, receipt, reclassified, record, reelection, remediation, representative, requirement, resistant, resolution, restate, Review, Schering, segregated, sensitivity, serve, service, settlement, shift, shown, specifically, SPIL, SPKK, strong, structure, suggesting, target, technical, thereunder, tolerated, traded, twelve, undiscounted, utility, variable, variety, worked

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SCLN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER

I,	Richard A. Waldron, Executive Vice President and Chief Financial Officer of SciClone Pharmaceuticals, Inc. (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

(1)	the Quarterly Report on Form 10-Q of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.


Date: May 8, 2007				/s/ Richard A. Waldron
				Richard A. Waldron
				Executive Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to SciClone Pharmaceuticals, Inc. and will be retained by SciClone Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.